Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

ASCO Connection

Effective May 2021, The Oncology Practice Insider newsletter consolidated with the ASCO Connection newsletter.

ASCO provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high-quality patient care, including updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. The biweekly ASCO Connection newsletter features the latest information on ASCO programs and resources for every member of the oncology community, including information tailored for practice administrators and practice leaders. Subscribe to the ASCO Connection newsletter for Practice News updates.

Visit the Quality Payment Program (QPP) Participation Status Tool to review your final 2022 eligibility status for the Merit-based Incentive Payment System (MIPS). CMS updated eligibility status based on review of Medicare Part B claims and Medicare Provider Enrollment, Chain, and Ownership System (PECOS) data from the second segment of the MIPS Eligibility Determination Period between October 1, 2021 – September 30, 2022.
On November 18, 2022, the Food and Drug Administration approved a new Monday-Wednesday-Friday dosing regimen for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze, Jazz Pharmaceuticals). Under the new regimen, patients should receive 25 mg/m2 intramuscularly on Monday and Wednesday mornings, and 50 mg/m2 intramuscularly on Friday afternoon. It also is approved to be administered every 48 hours at a dose of 25 mg/m2 intramuscularly.
The Food and Drug Administration (FDA) recently approved the following oncology drugs: 
On October 25, 2022, the Food and Drug Administration granted accelerated approval to teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
The Centers for Medicare & Medicaid Services (CMS) has expanded the archive for Doctors and Clinicians (DAC) in the Provider Data Catalog (PDC) on Care Compare. This expansion allows users to access historic Merit-based Incentive Payment System (MIPS) program performance data that were previously publicly reported in the PDC since the program’s inception in 2017.
On October 21, 2022, the Food and Drug Administration approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (uHCC). Read more.   
On September 30, 2022, the Food and Drug Administration granted accelerated approval to futibatinib (Lytgobi, Taiho Oncology, Inc.) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. Read more.
The Centers for Medicare & Medicaid Services (CMS) has extended the deadline to apply for the Enhancing Oncology Model (EOM) by 10 days to October 10, 2022 at 11:59 p.m. ET.